BIIB · NASDAQ · Biotechnology
Stock since the trade +10.4% · S&P 500 +0.8% · to Oct 1Traded 5 days after resultsStock 58% above its 52-week low and 7% below its high
3,875 → 3,282 shares held−15% of their stake
A board member of Biogen sold $121K of Biogen shares. Nobody planned it ahead of time.
Stock since the trade +6.9% · S&P 500 -0.9% · to Oct 1Traded 6 days after resultsStock within 4% of its 52-week high
3,282 → 2,689 shares held−18% of their stake
A board member of Biogen sold $119K of Biogen shares. Nobody planned it ahead of time.
Stock since the trade +14.0% · S&P 500 +12.1% · to Oct 1Traded 6 days after resultsStock within 3% of its 52-week high, after an 11% rise in the previous month
20K → 20K shares held
Biogen's Head of Pharm Ops and Tech spent $585 of their very own money to buy Biogen shares.
Stock since the trade +15.0% · S&P 500 +10.1% · to Oct 1Traded 3 days after resultsStock within 4% of its 52-week high
11K → 8,043.14 shares held−25% of their stake
Biogen's Head of Development sold $532K of Biogen shares. Nobody planned it ahead of time.
Stock since the trade +24.4% · S&P 500 +9.9% · to Oct 1Traded 4 days before resultsStock within 5% of its 52-week high
7,019.14 → 6,271.14 shares held−11% of their stake
Biogen's Head of Development sold $134K of Biogen shares. Nobody planned it ahead of time.
